<DOC>
	<DOCNO>NCT02734290</DOCNO>
	<brief_summary>The goal study establish safety tolerability pembrolizumab administer combination either two chemotherapy regimen ( weekly paclitaxel capecitabine ) unresectable/metastatic triple negative breast cancer ( MTNBC ) patient .</brief_summary>
	<brief_title>Standard Care Chemotherapy Plus Pembrolizumab Breast Cancer</brief_title>
	<detailed_description>In pilot phase , patient enrol one two experimental arm , select treat investigator ( arm A : pembrolizumab + weekly paclitaxel ; arm B : pembrolizumab + capecitabine ) . Subjects receive pembrolizumab via intravenous ( IV ) infusion 200mg every three week ( Q3W ) , continue treatment Q3W progression disease , initiation alternative cancer therapy , unacceptable toxicity , reason discontinue treatment occur , 24 month . Paclitaxel administer intervenously weekly schedule dose 80mg/m2 . Oral capecitabine administer total daily dose 4,000 mg ( 2,000 mg two time day ( abbreviate BID ) ) . Capecitabine administer intermittent therapy give day 1-7 14-day cycle .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Be willing able provide write informed consent/assent trial . Be 18 year age day sign informed consent . HER2negative breast cancer ( define immunohistochemistry ( IHC ) 01 ( ) IHC 2 situ hybridization ( ISH ) HER2 / centromere chromosome 17 ( CEP17 ) &lt; 2.0 ) ; ER PRnegative breast cancer ( define IHC &lt; 1 % ) ; Measurable metastatic unresectable disease base response evaluation criterion solid tumour ( RECIST ) 1.1 . Indicated treatment either weekly paclitaxel oral capecitabine , first secondline chemotherapy metastatic/unresectable setting ( determined consent investigator ) ; Be willing provide tissue newly obtain core excisional biopsy tumor lesion . Newlyobtained defined specimen obtain screen . Archival tissue acceptable intervene antineoplastic therapy administer , sufficient material available analysis ( see section 8.0 requirement ) ; Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Demonstrate adequate organ function define protocol define lab value Female subject childbearing potential must negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . Female subject childbearing potential must avoid become pregnant treatment . Men must avoid father child treatment . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has know history active TB ( Bacillus Tuberculosis ) Hypersensitivity pembrolizumab excipients . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study , Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Denosumab allow . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy alopecia exception criterion may qualify study . Has receive assign chemotherapy regimen previously metastatic setting , receive assigned chemotherapy regimen previously ( neo ) adjuvant set within 12 month consent ; If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Has know additional malignancy progress require active treatment last 5 year . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Has history of/active pneumonitis require treatment steroid history of/active interstitial lung disease . Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiprogrammed death 1 ( antiPD1 ) , antiprogrammed death ligand 1 ( antiPDL1 ) , antiprogrammed death ligand 2 ( antiPDL2 ) agent participate Mercksponsored pembrolizumab study . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B Hepatitis C. Has receive live vaccine within 30 day plan start study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine , allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>Human epidermal growth factor receptor 2 ( Her2 ) negative breast cancer</keyword>
	<keyword>Estrogen Receptor ( ER ) negative breast cancer</keyword>
	<keyword>Progesterone Receptor ( PR ) negative breast cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>